Publication date: Jul 08, 2025
One group received a low dose of the vaccine, which served as a control group. Now, encouraging results are in from the first human clinical trial to be conducted in the United States of a nasal COVID vaccine. However, definitive proof of efficacy will require larger trials designed specifically for this purpose. What’s next?By design, a phase 1 clinical trial involves low numbers of participants. “A single dose of this vaccine (CVXGA) was well tolerated. During the period of the trial from September 2021 to May 2023, various waves of SARS-CoV-2 variant infections emerged in the US. Participants were divided among four groups. It generated a wide spectrum of specific immune responses including mucosal and systemic immune responses. The other three groups had infection rates ranging from 11. 1% to 22. 2%.
| Concepts | Keywords |
|---|---|
| China | Clinical |
| February | Covid |
| Sickest | Dose |
| Vaccine | Generated |
| Group | |
| Groups | |
| Infection | |
| Nasal | |
| Participants | |
| Phase | |
| Received | |
| Trial | |
| Trials | |
| Vaccinated | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Nonoxynol-9 |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | infection |